OOO Smartpharmo

OOO Smartpharmo is a pharmaceutical importer based in Tashkent, Uzbekistan, specializing in the procurement of finished pharmaceutical formulations. The company operates as a buyer, sourcing a range of pharmaceutical products from international suppliers to meet the domestic demand in Uzbekistan. While specific details about its parent company are not publicly available, OOO Smartpharmo plays a significant role in the Uzbek pharmaceutical distribution network by ensuring the availability of essential medications.

The company's import activities are primarily focused on finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. This emphasis indicates a strategic approach to providing ready-to-use medications that are immediately available for distribution within the country. By importing these finished products, OOO Smartpharmo contributes to the efficiency of the pharmaceutical supply chain in Uzbekistan, reducing the need for local manufacturing and expediting the availability of critical drugs to healthcare providers and patients.

OOO Smartpharmo's distribution network is centered in Tashkent, the capital city of Uzbekistan, where its headquarters are located. The company imports pharmaceutical products from India, with a total import value of $700,000 USD across 14 shipments. The primary supplier is Combitic Global Caplet Private Limited, accounting for 100% of the shipments. While specific details about warehouse locations and logistics capabilities are not publicly disclosed, the company's operations suggest a focus on efficient distribution within Uzbekistan. The reliance on a single supplier indicates a streamlined logistics process, potentially reducing complexities in inventory management and distribution.

In Uzbekistan's pharmaceutical supply chain, OOO Smartpharmo functions as a pharmaceutical importer and distributor. By sourcing finished pharmaceutical formulations from international suppliers, the company ensures the availability of essential medications in the domestic market. This role is crucial in meeting the healthcare needs of the population, especially for drugs that are not produced locally. OOO Smartpharmo's activities support the healthcare infrastructure by providing timely access to a variety of pharmaceutical products, thereby contributing to the overall health and well-being of the community.

OOO Smartpharmo's sourcing strategy exhibits a high degree of concentration, with all 14 shipments originating from a single supplier, Combitic Global Caplet Private Limited. This single-source dependency could pose risks related to supply chain disruptions, such as production delays or quality control issues at the supplier's end. However, the consistent volume of imports and the exclusive relationship suggest a stable and reliable partnership. The supplier's ability to meet OOO Smartpharmo's demands without the need for additional suppliers indicates a strong and dependable sourcing arrangement. Nonetheless, the lack of diversification in the supplier base may limit the company's flexibility in responding to market changes or negotiating better terms.

The resilience of OOO Smartpharmo's supply chain is closely tied to the stability and reliability of Combitic Global Caplet Private Limited. With all imports sourced from this single supplier, any disruptions in their production or logistics could directly impact OOO Smartpharmo's ability to meet domestic demand. The absence of backup suppliers and limited formulation diversity further heighten this vulnerability. Additionally, the reliance on a single shipping route exposes the company to potential logistical challenges, such as transportation delays or geopolitical issues affecting trade routes. Ensuring that Combitic Global Caplet Private Limited adheres to international regulatory standards and maintains consistent product quality is essential for mitigating these risks.

OOO Smartpharmo's concentrated sourcing strategy positions the company to benefit from strong supplier relationships and potentially favorable terms due to the volume of business with Combitic Global Caplet Private Limited. However, this approach also exposes the company to risks associated with supply chain disruptions and limited flexibility in product offerings. For Indian exporters seeking to become alternative suppliers, this presents an opportunity to diversify OOO Smartpharmo's supplier base by offering competitive pricing, reliable delivery schedules, and adherence to quality standards. By addressing these factors, Indian exporters can position themselves as viable partners, potentially reducing OOO Smartpharmo's dependency on a single supplier and enhancing the company's supply chain resilience.

The pharmaceutical industry in Uzbekistan is regulated by the Ministry of Health, which oversees the registration, import, and distribution of pharmaceutical products. Key legislation governing pharmaceutical imports includes the Law on Medicines and Pharmaceutical Activities, which outlines the procedures for state registration and quality control of medicines. The marketing authorization pathway for Indian generics involves obtaining state registration from the Ministry of Health, which may require submission of product dossiers, clinical trial data, and compliance with Good Manufacturing Practice (GMP) standards. Additionally, Uzbekistan recognizes marketing authorizations from certain countries and organizations, facilitating a streamlined registration process for products approved in these jurisdictions.

Import licensing in Uzbekistan requires pharmaceutical companies to obtain state registration for each product they intend to import. This process involves submitting detailed product information, including manufacturing details, quality control measures, and clinical data, to the Ministry of Health. Uzbekistan recognizes GMP certificates from the European Union, World Health Organization (WHO), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S), which can expedite the registration process for foreign manufacturers. Wholesale distribution authorization is also mandatory, ensuring that companies comply with local regulations regarding storage, handling, and distribution of pharmaceutical products.

Imported pharmaceutical products must undergo batch testing to ensure compliance with Uzbekistan's quality standards. Stability requirements are enforced to guarantee that products maintain their efficacy and safety throughout their shelf life. Labeling must be in the Uzbek language, providing consumers with essential information about the product's usage, dosage, and potential side effects. Serialization mandates are in place to track and trace pharmaceutical products throughout the supply chain, enhancing transparency and reducing the risk of counterfeit products entering the market.

In January 2025, Uzbekistan introduced a 2% customs duty on the import of certain pharmaceutical products, including antibiotics, painkillers, anti-inflammatory drugs, antiviral medications, hormonal treatments, and other specified categories. This change aims to accelerate the development of Uzbekistan's pharmaceutical sector by encouraging local production and reducing reliance on imports. The decree amended previous regulations, setting the duty rate for goods under HS code 3004 at 2%, up from 0%. This policy shift may impact the cost structure for importers like OOO Smartpharmo and could influence sourcing decisions and pricing strategies.

OOO Smartpharmo's product strategy focuses on importing finished pharmaceutical formulations in the therapeutic categories of Antihistamines & Allergy, Gastrointestinal, and Analgesics & Antipyretics. This selection aligns with common health concerns in Uzbekistan, addressing conditions such as allergies, digestive disorders, and pain management. The market demand for these products is driven by the prevalence of these health issues among the population, necessitating a steady supply of effective medications. By concentrating on these therapeutic areas, OOO Smartpharmo aims to meet critical healthcare needs and maintain a competitive edge in the pharmaceutical market.

OOO Smartpharmo's sourcing strategy is centered on importing generic drugs from India, focusing on finished pharmaceutical formulations. The company's preference for specific formulations, such as Chlorpheniramine, Ranitidine, and Diclofenac, indicates a targeted approach to meet the therapeutic needs of the Uzbek market. India's established pharmaceutical manufacturing capabilities and adherence to international quality standards make it a suitable partner for OOO Smartpharmo's procurement needs. This sourcing profile enables the company to offer a range of affordable and effective medications to the Uzbek population.

Based on its product mix, OOO Smartpharmo serves the wholesale distribution segment of the Uzbekistan pharmaceutical market. By importing and distributing finished pharmaceutical formulations, the company supplies medications to various healthcare providers, including hospitals, clinics, and pharmacies. This positioning allows OOO Smartpharmo to play a pivotal role in ensuring the availability of essential drugs across the country, thereby contributing to the overall healthcare infrastructure.

There is a realistic opportunity for new Indian suppliers to collaborate with OOO Smartpharmo, especially given the company's concentrated sourcing strategy. By offering competitive pricing, reliable delivery schedules, and adherence to quality standards, Indian exporters can position themselves as viable partners. Diversifying OOO Smartpharmo's supplier base could enhance the company's supply chain resilience and provide access to a broader range of pharmaceutical products. Identifying gaps in the current sourcing strategy, such as unmet therapeutic needs or emerging market trends, can further inform potential partnerships.

Indian exporters seeking to supply OOO Smartpharmo and the Uzbekistan market must ensure compliance with Uzbekistan's regulatory requirements. This includes obtaining state registration for each product, adhering to Good Manufacturing Practice (GMP) standards recognized by Uzbekistan, and ensuring that products meet quality control measures mandated by the Ministry of Health. Additionally, labeling must be in the Uzbek language, and products must comply with serialization mandates to facilitate traceability.

To establish a relationship with OOO Smartpharmo, Indian exporters should initiate contact through the company's provided communication channels.